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Introduction {#sec005}
============

Fibroblast growth factor 21 (FGF21) is a peptide hormone synthesised and secreted by several organs (mainly the liver) and is implicated in growth and energy balance \[[@pone.0235557.ref001]\]. Recent research has provided preliminary evidence that FGF21 might have a role in regulating thirst and drinking behaviours in rodents \[[@pone.0235557.ref002],[@pone.0235557.ref003]\]. These behaviours are controlled neurologically: hypertonicity is detected by the central nervous system, relaying this information to the lamina terminalis which contains stretch-sensitive ion channels in areas such as the organum vasculosum \[[@pone.0235557.ref004]\]. This osmoreception stimulates neurons in the paraventricular nucleus and hypothalamus and results in the secretion of arginine vasopressin (AVP) \[[@pone.0235557.ref005],[@pone.0235557.ref006]\], facilitating reductions in renal water losses thus mitigating further losses in body water. During hypohydration, AVP is secreted into circulation from the hypothalamus in order to reduce urinary water losses, thus aiding in blood pressure regulation by maintaining blood volume \[[@pone.0235557.ref005]\]. Simultaneously, the elevated extracellular osmolality stimulates thirst to encourage fluid ingestion or water-seeking behaviour \[[@pone.0235557.ref007]\]. Arginine vasopressin is part of the hypothalamic-pituitary-adrenal (HPA) axis. Under stress, AVP potentiates the effects of corticoptropin-releasing hormone (CRH) on adrenocorticotropic hormone and cortisol secretion \[[@pone.0235557.ref008],[@pone.0235557.ref009]\] from the pituitary and adrenal glands, respectively.

Fibroblast growth factor 21 has been shown to stimulate the HPA axis in response to prolonged fasting in mice \[[@pone.0235557.ref010],[@pone.0235557.ref011]\]. However, FGF21 may also act to reduce AVP in the suprachiasmatic nucleus, \[[@pone.0235557.ref011]\] meaning the role of FGF21 in thirst could be via pathways which are independent of AVP or hydration status. Rodent studies have demonstrated increased fluid ingestion after FGF21 administration \[[@pone.0235557.ref002],[@pone.0235557.ref003],[@pone.0235557.ref012]\] or a preference for plain water over sweetened water in FGF21-transgenic mice \[[@pone.0235557.ref013],[@pone.0235557.ref014]\].

In rodents with free access to chow and water, intravenous infusion of PF-05231023 (a long-lasting FGF21 analogue) did not alter plasma osmolality, but did increase water intake by \~20% after 48 h, with no change in food intake \[[@pone.0235557.ref002]\]. Urinary output also increased after PF-05231023 infusion including greater absolute excretion of electrolytes. Interestingly this increase in urinary output was greatest (\~40% higher than control rats) after 24 h, suggesting FGF21 caused increased urination, which resulted in greater water intake (perhaps indicative of higher thirst). Conversely, PF-05231023 infusion did not have these effects in fluid restricted (hypohydrated) rats. Despite the theoretical relationship between FGF21 and the HPA axis, no differences were seen between treatment and control rats in hypothalamic AVP or CRH expression, concordant with other similar research \[[@pone.0235557.ref003]\].

Considering FGF21 alters fluid balance, it is perhaps unsurprising that it has also been implicated in blood pressure in accordance with other hormones related to fluid balance (e.g. AVP). In PF-05231023-infused rats, both heart rate and blood pressure increased compared to control rats \[[@pone.0235557.ref002]\], though this has not been replicated in mice \[[@pone.0235557.ref003]\]. Such findings indicate that FGF21 may have a role in raising blood pressure in a euhydrated state, causing increased urination which increases thirst and ultimately results in fluid ingestion; this chain of events is currently unclear since polydipsia in mice does not appear to be secondary to polyuria, thus warranting further investigation \[[@pone.0235557.ref003]\]. It is unlikely that this cascade is mediated by the kidneys as β-klotho (an FGF21 cofactor involved in FGF21 activity and receptor binding) is expressed only in very low concentrations in the kidneys \[[@pone.0235557.ref002]\]. Thus, FGF21-mediated drinking responses appear to bypass typical thirst regulatory pathways, such as increased plasma osmolality and AVP secretion.

However, there is evidence that the effect of FGF21 in rodents may be different to primates. For example, in rodents, food intake does not change with PF-05231023 infusion \[[@pone.0235557.ref002]\], whereas in cynomolgus monkeys and humans food intake decreases after treatment \[[@pone.0235557.ref015]\]. There is, however, a noted lack of causal human data \[[@pone.0235557.ref016]\], though recent work has shown PF-05231023 infusion in humans with obesity and hypertriglyceridaemia to increase blood pressure \[[@pone.0235557.ref017]\], corroborating findings in rodents. In humans, mild hypohydration (\< 2% body mass fluctuation) is commonly achieved during daily living \[[@pone.0235557.ref018]\]; thus it is of interest to understand whether hydration status can impact FGF21. Whilst Song *et al*. \[[@pone.0235557.ref003]\] found FGF21 to be unaffected after water deprivation in mice, the relationship between FGF21 and hydration status in humans is currently unknown. As FGF21 may be involved in adipocyte glucose uptake \[[@pone.0235557.ref019]\], and in aiding in insulin sensitivity and glycaemic regulation \[[@pone.0235557.ref001]\], there may be important therapeutic benefits to understanding whether FGF21 can be manipulated by hydration status.

We recently conducted a randomised crossover trial investigating the effect of hydration status on glycaemic regulation, finding mild (\~2%) hypohydration did not impact glycaemia or insulinaemia *versus* euhydration in healthy adults \[[@pone.0235557.ref020]\]. After completion of the study, we were able to measure FGF21 concentrations in the remaining fasted plasma samples which we aim to describe herein. Due to the findings of previous research showing FGF21 appears to induce dehydration (e.g. increased urination), we hypothesised that hypohydration (HYPO) would lead to a decrease in fasted plasma FGF21 concentrations compared to when participants were rehydrated (RE), due to water losses suppressing secretory diuretic hormones.

Materials and methods {#sec006}
=====================

Participants {#sec007}
------------

Participants were recruited using posters at the University of Bath (South West England), which is where the research was conducted, between June 2016 and January 2017. The inclusion criteria required participants to be healthy and not taking prescribed medication or supplements, with the exception of hormonal contraceptives. Therefore, our exclusion criteria were: age \< 18 y or ≥ 60 y, self-reported metabolic disease (no body mass restrictions, except self-reported weight loss \> 5 kg in previous 6 mo), drug dependence, and pregnancy/breastfeeding. All participants gave fully informed consent to undergo the protocol and for their samples and data to be used as appropriate for the project.

We recruited sixteen healthy adults who successfully participated in the study after giving fully informed consent ([Table 1](#pone.0235557.t001){ref-type="table"}). Participants were not offered any incentive to participate, beyond their individualised feedback; considering this, the affluence of the city of Bath, and our inclusion criteria focused on healthy adults, our sample is representative of healthy middle-class younger adults (both men and women), interested in their health. Ethical approval was granted from the NHS Health Research Authority, reference: 16/SW/0057 (trial registration: Clinicaltrials.gov: NCT02841449; Open Science Framework: osf.io/ptq7m). Participants were randomised via simple randomisation to be in either the hypohydrated (HYPO) trial arm, or rehydrated (RE) trial arm first.

10.1371/journal.pone.0235557.t001

###### Participant characteristics (n = 16).

![](pone.0235557.t001){#pone.0235557.t001g}

  Participant characteristic   Mean ± standard deviation
  ---------------------------- ---------------------------
  Sex (n female)               8
  Age (y)                      30 ± 9
  Body mass (kg)               71.7 ± 9.6
  Body mass index (kg/m^2^)    24.0 ± 3.4

Study design {#sec008}
------------

The methods have been previously described in full \[[@pone.0235557.ref020]\]. This was a randomised crossover trial with a 5--35 day washout period. Three days prior to the intervention, participants replicated their diet (including fluids) and activity patterns. On the third day, participants were instructed to consume ≥ 40 mL∙kg^-1^ lean body mass of non-alcoholic fluid to ensure euhydration prior to starting the protocol \[[@pone.0235557.ref020]\].

Following these pre-trial controls, participants came to the laboratory after overnight food and fluid abstention and had a fasted (baseline) blood sample drawn in a euhydrated state, before undergoing a dehydration protocol via 60 min in a heat tent (\~45°C) wearing a sweat suit (RDX EVA Nylon Sauna Sweat Suit). Participants then consumed a sandwich containing ≥ 1 g salt to maximise fluid retention and serum osmolality changes. For HYPO, 3 mL∙kg^-1^ of plain water was provided, compared to 40 mL∙kg^-1^ lean body mass plus 150% water losses from the heat tent procedure for RE. Participants were only permitted to consume low water content foods and the water provided (i.e. no other fluids). Diet and activity were replicated on the subsequent trial arm, with the exception of water intake.

The next day, participants arrived at the laboratory after overnight food and fluid abstention. A fasted arterialised-venous blood sample was obtained from an antecubital vein which was used to assess circulating FGF21 concentrations, followed by a two hour oral glucose tolerance test \[[@pone.0235557.ref020]\] and a series of appetite tasks \[[@pone.0235557.ref021]\]. Participants then had a 5--35 day washout period before repeating the protocol under the other intervention arm.

Biochemical analysis {#sec009}
--------------------

Biochemical analysis for the primary analytes of the study have previously been described \[[@pone.0235557.ref020]\]. Fibroblast growth factor 21 was measured via electrochemiluminescence (MSD, Mesoscale Diagnostics LLC; in-house coefficient of variation 5.4%).

Statistical analysis {#sec010}
--------------------

Data were checked for normality visually via histogram of the raw data, and PP and QQ plots of the standardised residuals, as previously described \[[@pone.0235557.ref020]\]. The FGF21 data were not normally distributed, therefore the Wilcoxon test was used for inferential purposes. Spearman's *rho* was conducted to understand the association between fasted plasma FGF21 concentrations and change from baseline in body mass, urine osmolality, serum osmolality, plasma copeptin concentration, serum glucose and insulin concentrations, and age, in order to determine if there were any factors which might be associated with a stronger FGF21 response. All analyses had an alpha level of ≤ 0.05.

Results {#sec011}
=======

Participants lost 1.9 ± 1.2% body mass after HYPO with weight stability after RE \[[@pone.0235557.ref020]\]. This body mass loss was accompanied by expected hypohydration-induced increases in urine specific gravity, urine osmolality, serum osmolality, and plasma copeptin concentration (as a marker of AVP) and a reduction in cross-sectional muscle area (as a proxy for cell volume) \[[@pone.0235557.ref020]\]. Compared to RE, HYPO did not alter fasted or postprandial serum glucose or insulin concentrations, or plasma ACTH or cortisol concentrations \[[@pone.0235557.ref020]\].

The median paired difference from RE to HYPO was -37 pg∙mL^-1^ (IQR -125, 10 pg∙mL^-1^; *P* = 0.278; [Fig 1](#pone.0235557.g001){ref-type="fig"}). The average plasma FGF21 concentration during HYPO was 458 ± 462 pg∙mL^-1^, compared to 467 ± 438 pg∙mL^-1^ during RE; mean paired difference -9 ± 173 pg∙mL^-1^. There were no associations with fasted plasma FGF21 concentrations and change in any of the hydration or metabolic factors explored ([Table 2](#pone.0235557.t002){ref-type="table"}).

![(A) Individual fasted FGF21 concentrations RE compared to HYPO. (B) Individual change scores from RE to HYPO in order of magnitude of change. Abbreviations: FGF21, fibroblast growth factor 21; HYPO, hypohydrated trial arm; RE, rehydrated trial arm.](pone.0235557.g001){#pone.0235557.g001}

10.1371/journal.pone.0235557.t002

###### Associations between fasted plasma FGF21 concentrations in a hypohydrated and euhydrated state and change from baseline in fasted markers of hydration status and metabolic health.

![](pone.0235557.t002){#pone.0235557.t002g}

                       Hypohydrated trial arm   Euhydrated trial arm            
  -------------------- ------------------------ ---------------------- -------- -------
  Age                  -0.068                   0.802                  0.108    0.691
  Δ Body mass          -0.259                   0.333                  0.277    0.298
  Δ Urine osmolality   -0.216                   0.421                  -0.097   0.721
  Δ Serum osmolality   0.126                    0.641                  -0.145   0.592
  Δ Plasma copeptin    -0.107                   0.704                  0.221    0.428
  Δ Serum glucose      0.306                    0.249                  -0.127   0.640
  Δ Serum insulin      -0.494                   0.052                  -0.481   0.059

Analyses conducted using Spearman's *rho*. Abbreviations: FGF21, fibroblast growth factor 21.

Of the 16 participants, five (aged 22--44 y, median 25 y; n = 4 women) showed an increased in plasma FGF21 concentrations during HYPO compared to RE (ranging from **Δ** 4 to 518 pg∙mL^-1^, median **Δ** 96 pg∙mL^-1^). Comparatively, the remaining 11 participants (aged 22--50 y, median 25 y; n = 4 women) showed a decreased in plasma FGF21 concentrations during HYPO compared to RE (ranging from **Δ** -188 to -0.2 pg∙mL^-1^, median **Δ** -56 pg∙mL^-1^). There were no obvious trends in the data that appeared to explain whether participants responded as per our hypothesis or not.

Discussion {#sec012}
==========

Contrary to our hypothesis, hypohydration did not decrease fasted plasma FGF21 concentrations. As thirst and desire for higher water content foods was higher during HYPO \[[@pone.0235557.ref021]\] we found no evidence that a mechanism by which hypohydration is implicated in drinking behaviours in humans is via FGF21 secretion. In rodent models, FGF21 altered drinking behaviours likely via increased urine output. Combined with our findings in humans, this potentially highlights that the relationship is a unidirectional effect. In other words, whilst FGF21 can alter ingestive behaviours resulting in some physiological changes seen during euhydration (i.e. increased urinary output), manipulating hydration itself does not appear to result in differences in plasma FGF21 concentrations.

Alternatively, there could be a causal effect in humans, but this requires a stronger stimulus than the modest level of hypohydration we achieved (\~2% body mass loss; serum osmolality 296 mOsm/kg HYPO *versus* 286 mOsm/kg RE), and/or requires chronic fluid deprivation. Such chronic adaptive effects on FGF21 would accord with starvation models in humans whereby FGF21 elevations occur after \~7 days \[[@pone.0235557.ref022]\]. Whilst the mechanisms surrounding starvation and fluid deprivation with regard to FGF21 responses may differ, this comparison perhaps highlights a role of FGF21 in chronic adaptations---something our study was not designed to measure---thus warranting further exploration in humans.

Additionally, FGF21 theoretically can stimulate the HPA axis, particularly under stress such as prolonged fasting \[[@pone.0235557.ref010]\]. In our original study, after HYPO, AVP (as measured by copeptin) was elevated to levels seen in those with type 2 diabetes and the metabolic syndrome \[[@pone.0235557.ref023],[@pone.0235557.ref024]\], with no difference in FGF21, yet again highlighting the unidirectionality of this relationship compared to the rodent literature. No differences were found in plasma ACTH or cortisol concentrations \[[@pone.0235557.ref020]\], thus we are unable to make inferences as to the relationship between these hormones and FGF21 in the context of hydration status. We also explored other factors which may moderate circulating FGF21 concentrations, such as age and the level of hypohydration, finding no association, though our conclusions are limited by the relatively small sample size.

In relation to metabolic states, FGF21 may respond specifically to hypermetabolic conditions whereby total energy expenditure has increase resulting in an increase in energy intake. This in turn drives thirst and therefore drinking behaviour \[[@pone.0235557.ref025]\]. Thus an increase in thirst and drinking behaviours may be a result of elevations in FGF21 (which increases energy expenditure in mice \[[@pone.0235557.ref026]\]). Our data provide support for this pathway as hydration status itself did not alter thirst or biomarkers of hydration status.

The main aim of the original study was to investigate the effect of hydration status on fasted and postprandial glycaemia, ultimately finding a null effect \[[@pone.0235557.ref020]\]. As FGF21 is implicated in improved insulin sensitivity and glucose tolerance \[[@pone.0235557.ref001],[@pone.0235557.ref019]\], it is perhaps unsurprising in this context that no differences were found. Nonetheless, future work should investigate the postprandial FGF21 response according to hydration status; this is particularly important considering our present analysis was decided *post hoc* and therefore not pre-specified in our research plan or trial registration. This is particularly important as previous work has suggested the thirst-inducing effects of FGF21 to be context-specific, i.e. most prominent in conditions known to induce hypohydration such as prolonged fasting or during a ketogenic diet \[[@pone.0235557.ref003]\]. It therefore seems paradoxical that dehydrating dietary conditions can amplify the effects of FGF21 but hypohydration itself does not appear to impact FGF21 concentrations.

The initial study was powered to investigate the glycaemic response to hypohydration compared to euhydration. It may be that there is a small but meaningful response, which we may not have been able to detect due to lack of statistical power for FGF21 as the outcome; equally, there may be unmeasured characteristics resulting in responders or non-responders. As such, the large variance between-participants should be further investigated in larger samples as some concentrations were at levels that are perhaps found in those with obesity or diabetes. Additionally, the kit we used to analyse FGF21 does not specify whether total or active FGF21 is measured; considering its calibration using full-length FGF21 with a predicted molecular mass of 20 kDa, it is most likely we measured active FGF21, which has been shown to the primary circulating form of FGF21 \[[@pone.0235557.ref027]\].

To our knowledge, this is the first study to examine the causal role of hydration status on circulating FGF21 concentrations in humans. Hydration status did not appear to affect fasted plasma FGF21 concentrations, suggesting that the evidence from rodent FGF21 infusion studies is unidirectional (i.e. FGF21 can cause dehydration, but not *vice versa*). Due to the small sample size, these findings should be taken as preliminary and used as a basis to build new hypotheses pertaining to FGF21-hydration status interactions. Thus, further research should investigate whether FGF21 is altered by hydration status in larger samples, in both the fasted and fed state, as well as investigate whether this is another mechanism (beyond osmolality and AVP changes) implicated in human drinking behaviours. Additionally, future work should aim to answer current outstanding questions such as whether there is a differential FGF21 response to hydration status with a greater degree of hypohydration, and whether this is influenced by the duration of hypohydration.

Supporting information {#sec013}
======================
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Click here for additional data file.
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Additionally, we have included a table with key participant characteristics: age, sex weight, BMI.

\[Editor comment\] 2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please specify whether trial participants consented to the use of samples in additional analyses (not included by the original trial). If not, please specify whether you obtained separate ethics approval for this analysis.

\[Author response\] We obtained fully informed consent to conduct all the necessary procedures on participants, such as cannulation and taking a pre-specified amount of blood. Participants consented for their samples to be used for relevant analyses, but we had not specified exactly what these analyses would be. Therefore, FGF21 analyses were consensually covered and did not require further approval or consent. As FGF21 was unplanned, it was not included on our trial registration unlike the main analytes, such as glucose and insulin. We have added the following to the manuscript:

"All participants gave fully informed consent to undergo the protocol and for their samples and data to be used as appropriate for the project." (lines 121-122)

\[Editor comment\] 3. Thank you for including the following funding information within the acknowledgements section; \"This work was supported by the Economic and Social Research Council (grant no.: ES/J50015X/1) and the European Hydration Institute Graduate Research Grant. \"

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

\"HAC is funded by the Economic and Social Research Council (grant no.: ES/J50015X/1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

\[Author response\] We have removed this from the manuscript and would appreciate it being added to our funding statement. Apologies for the mix-up.

Reviewers\' comments

\[Reviewer comment\] Reviewer \#1: An important study with broadly interesting results regarding FGF21 involvement in fluid balance in humans.

A few minor points. On line 75/76 authors state that PF-05231023 reduces blood pressure, but the manuscript they cite shows the reverse. On line 78 the Song reference is stated to have used rats, but the species used in this study were mice.

\[Author response\] Thank you for highlighting these errors, we have amended as appropriate (changes in red):

"though recent work has shown PF-05231023 infusion in humans with obesity and hypertriglyceridaemia to reduce blood pressure, corroborating findings in rodents." (lines 94-95)

"Whilst Song et al.3 found FGF21 to be unaffected after water deprivation in smice..." (line 98)

\[Reviewer comment\] Regarding the hypothesis in the introduction, wouldn\'t it be more logical to expect that heat induced water loss from sweat would suppress secretion of a diuretic factor from the liver?

\[Author response\] Thank you for this insight. Since there was no causal human work to go from, our hypothesis was built on reverse causality from the findings of previous research. However, your hypothesis fits the causal direction of our study design better and makes logical sense. We have therefore amended our hypothesis and discussion as follows (changes in red):

"Due to the findings of previous research showing FGF21 appears to induce dehydration (e.g. increased urination), we hypothesised that hypohydration (HYPO) would lead to a decrease in fasted plasma FGF21 concentrations compared to when participants were rehydrated (RE), due to water losses suppressing secretory diuretic hormones." (lines 110-112)

"Contrary to our hypothesis, hypohydration did not decrease fasted plasma FGF21 concentrations." (line 219)

Major point:

\[Reviewer comment\] Would correcting FGF21 levels for plasma volume depletion affect these results? (i.e. to albumin or whatever is standard).

\[Author response\] We agree that correcting for plasma volume would be interesting, and as such we did measure plasma volume using haematocrit and haemoglobin. However, we made a methodological error in standardising posture properly during the study, which meant our plasma volume data were not reliable. We outlined this in our original manuscript of the main study findings (doi: 10.1152/japplphysiol.00771.2018) as well as providing the (unreliable) data with an explanatory note in our published data for others to scrutinise (<https://researchdata.bath.ac.uk/id/eprint/547>).

Whilst mechanistically interesting to correct for plasma volume, uncorrected data still provide valid results as most studies do not measure plasma volume. Nonetheless, we do appreciate these would have been valuable data to have had.

\[Reviewer comment\] Reviewer \#2: This work by Carroll and colleagues explores the effect of hydration on circulating levels of the endocrine factor FGF21 in humans. Previous work in rodents has suggested that FGF21 could regulate thirst and the authors examined whether plasma FGF21 levels were physiologically altered by hydration status. These data are important for the field and warrant publication, but a few minor issues need to be addressed beforehand.

\[Author response\] We appreciate your overall positive review and hope we have addressed the issues you raised below.

\[Reviewer comment\] 1) It would be worthwhile to include in the introduction and discussion that FGF21 has been shown to increase fluid intake primarily under potentially hypermetabolic conditions. It has been proposed that this increase in fluid intake in response to FGF21 is actually due to increases in food intake (i.e., prandial thirst) (BonDurant and Potthoff; PMID: 29727594).

\[Author response\] Thank you for this article and idea. Since understanding the interaction between energy expenditure, food, and thirst was not the aim of the study, we have acknowledged this theory in our discussion only, as follows:

"In relation to metabolic states, FGF21 may respond specifically to hypermetabolic conditions whereby total energy expenditure has increase resulting in an increase in energy intake. This in turn drives thirst and therefore drinking behaviour \[25\]. Thus an increase in thirst and drinking behaviours may be a result of elevations in FGF21 (which increases energy expenditure in mice \[26\]). Our data provide support for this pathway as hydration status itself did not alter thirst or biomarkers of hydration status." (lines 249-254)

\[Reviewer comment\] 2) FGF21 does not increase fluid intake under conditions of high sucrose (von Holstein-Rathlou et al.; PMID: 26724858). This citation was also omitted on the sweet taste reference.

\[Author response\] Apologies for not including this; we have added the citation to the introduction regarding sweet taste (line 64). However, we are unsure of the link to our manuscript and fluid intake under high sucrose conditions.

\[Reviewer comment\] 3) A potential issue is how FGF21 levels were measured. The authors need to provide more information about this electrochemiluminescence assay. What part of FGF21 does this assay measure. As the authors may know, FGF21 is cleaved and inactivated on the C-terminus. Thus, did the authors measure total or "active" FGF21? These issues should also be addressed in the discussion as potential limitation of the results.

\[Author response\] Thank you for raising this relevant issue of which form (total or active) of FGF21 was targeted by the assay used in this study. The FGF21 assay performed here was a commercially available electrochemiluminescence assay produced and supplied by Mesoscale Diagnostics (MSD). We contacted MSD in order to answer your query. MSD informed us that it has, unfortunately, not been tested in-house by MSD as to which form of FGF21 is targeted by this human assay. However, the calibrator used in this assay is full length human FGF21 expressed in E.coli with a predicted molecular mass of 20 kDa. Thus it is likely, though not guaranteed, that we measured total FGF21. We have added in the manuscript the following to account for the ambiguity:

"Additionally, the kit we used to analyse FGF21 does not specify whether total or active FGF21 is measured; considering its calibration using full-length FGF21 with a predicted molecular mass of 20 kDa, it is most likely we measured active FGF21, which has been shown to the primary circulating form of FGF21 \[27\]." (lines 272-275)

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

\[Author response\] We have done this and believe our figure meets PLoS ONE specifications.
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The effect of hydration status on plasma FGF21 concentrations in humans
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Dear Dr. Carroll,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 25 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Jo Edward Lewis, Ph.D

Academic Editor

PLOS ONE
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#3: Interesting sub analyis, although with some limitations

The present is a crossover RCT: this should be added in the title,. I would write; a sub analysis of a crossover RCT

Methods: tables should be put at end and not in the text

Methods: sample size calculation was not performed for this rct: this should be put in limitation. Moreover this sub analysis was not prespecificed and also this should be added in limitation section

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#3: Yes: Fabrizio D\'Ascenzo

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

13 Jun 2020

\[Reviewer comment\] Interesting sub analyis, although with some limitations. The present is a crossover RCT: this should be added in the title,. I would write; a sub analysis of a crossover RCT

\[Author response\] Thank you for this helpful comment. We have changed the title to "The effect of hydration status on plasma FGF21 concentrations in humans: A subanalysis of a randomised crossover trial".

\[Reviewer comment\] Methods: tables should be put at end and not in the text

\[Author response\] We followed PLoS author guidelines and inserted tables immediately after the paragraph they were first cited.

\[Reviewer comment\] Methods: sample size calculation was not performed for this rct: this should be put in limitation.

\[Author response\] Lines 264-270 discussed that the study was powered for glycaemia not FGF21. We have added the following to this paragraph to emphasise the point:

"It may be that there is a small but meaningful response, which we may not have been able to detect due to lack of statistical power for FGF21 as the outcome" (line 266)

\[Reviewer comment\] Moreover this sub analysis was not prespecificed and also this should be added in limitation section

\[Author response\] We hope it was clear this was not a pre-specified outcome in our introduction, but have reiterated this point in our discussion:

"Nonetheless, future work should investigate the postprandial FGF21 response according to hydration status; this is particularly important considering our present analysis was decided post hoc and therefore not pre-specified in our research plan or trial registration." (lines 256-258)

Additional edit: Since resubmitting the manuscript, the first author has changed institutional affiliation, and this has been amended on the title page.
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Dear Dr. Carroll,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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Jo Edward Lewis, Ph.D

Academic Editor
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Dear Dr. Carroll:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.
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PLOS ONE Editorial Office Staff
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